이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Johnson & Johnson 미래 성장

Future 기준 확인 2/6

Johnson & Johnson (는) 각각 연간 10.8% 및 3.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 11.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 36% 로 예상됩니다.

주요 정보

7.1%

수익 성장률

8.9%

EPS 성장률

Pharmaceuticals 수익 성장	23.5%
매출 성장률	3.4%
향후 자기자본 수익률	34.6%
애널리스트 커버리지	Good
마지막 업데이트	09 Sep 2024

최근 미래 성장 업데이트

Recent updates

Johnson & Johnson: A Lot Of Moving Parts, But Perhaps Finally Lurching In The Right Direction

Jul 03

There's Reason For Concern Over Johnson & Johnson's (NYSE:JNJ) Price

Jun 10

수익 및 매출 성장 예측

NYSE:JNJ - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	94,325	22,739	23,364	27,819	16
12/31/2025	91,099	21,347	22,788	27,287	19
12/31/2024	88,486	19,353	22,415	24,349	19
6/30/2024	86,576	16,382	19,833	24,642	N/A
3/31/2024	85,648	17,072	18,234	23,191	N/A
12/31/2023	85,159	13,326	17,778	22,791	N/A
10/1/2023	83,703	12,421	15,737	20,278	N/A
7/2/2023	82,348	12,422	14,547	19,073	N/A
4/2/2023	77,458	10,730	16,207	20,472	N/A
1/1/2023	79,990	16,370	17,185	21,194	N/A
10/2/2022	84,855	17,879	17,739	21,576	N/A
7/3/2022	88,197	17,236	19,950	23,582	N/A
4/3/2022	94,880	19,830	19,733	23,315	N/A
1/2/2022	78,740	17,801	19,758	23,410	N/A
10/3/2021	91,446	17,880	22,461	26,021	N/A
7/4/2021	89,190	17,767	22,564	26,114	N/A
4/4/2021	84,214	15,115	20,853	24,252	N/A
1/3/2021	82,584	14,714	20,189	23,536	N/A
9/27/2020	80,856	16,986	18,307	21,591	N/A
6/28/2020	80,503	15,185	17,443	20,735	N/A
3/29/2020	82,729	17,166	19,764	23,231	N/A
12/29/2019	82,059	15,119	19,918	23,416	N/A
9/29/2019	81,706	14,151	19,706	23,262	N/A
6/30/2019	81,325	16,332	18,377	22,007	N/A
3/31/2019	81,593	14,679	18,470	22,138	N/A
12/30/2018	81,581	15,297	18,531	22,201	N/A
9/30/2018	81,382	1,542	18,470	22,062	N/A
7/1/2018	80,684	1,372	18,493	22,056	N/A
4/1/2018	78,693	1,245	N/A	21,749	N/A
12/31/2017	76,450	1,300	N/A	21,056	N/A
10/1/2017	74,361	15,827	N/A	21,604	N/A
7/2/2017	72,531	16,335	N/A	20,699	N/A
4/2/2017	72,174	16,505	N/A	19,491	N/A
1/1/2017	71,890	16,540	N/A	18,767	N/A
10/2/2016	71,595	15,941	N/A	17,199	N/A
7/3/2016	70,877	15,027	N/A	17,978	N/A
4/3/2016	70,182	15,546	N/A	18,886	N/A
1/3/2016	70,074	15,409	N/A	19,569	N/A
9/27/2015	70,517	14,715	N/A	18,849	N/A
6/28/2015	71,882	16,106	N/A	17,363	N/A
3/29/2015	73,590	15,916	N/A	17,420	N/A
12/28/2014	74,331	16,323	N/A	18,710	N/A
9/28/2014	74,232	17,321	N/A	18,245	N/A
6/29/2014	73,340	15,554	N/A	19,538	N/A
3/30/2014	71,722	15,061	N/A	19,060	N/A
12/29/2013	71,312	13,831	N/A	17,414	N/A
9/29/2013	70,515	12,879	N/A	16,651	N/A

애널리스트 미래 성장 예측

수입 대 저축률: JNJ 의 연간 예상 수익 증가율( 10.8% )이 saving rate( 2.4% 보다 높습니다. ).

수익 vs 시장: JNJ 의 연간 수익( 10.8% ) US 시장( 14.8% 보다 느리게 성장할 것으로 예상됩니다. 14.8% 연간).

고성장 수익: JNJ 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: JNJ 의 수익(연간 4.4% ) US 시장( 8.7% 보다 느리게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: JNJ 의 수익(연간 4.4% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: JNJ 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 38.6 %)

Johnson & Johnson 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Consensus EPS estimates fall by 10%

Recent updates

Why Investors Shouldn't Be Surprised By Johnson & Johnson's (NYSE:JNJ) P/E

Johnson & Johnson to Report Q4, 2024 Results on Jan 22, 2025

Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis

Johnson & Johnson Announces Executive Changes

We Think Johnson & Johnson (NYSE:JNJ) Can Stay On Top Of Its Debt

Johnson & Johnson: Don't Bet Against Double Compounding

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze™ (Lazertinib)

Upcoming dividend of US$1.24 per share

Johnson & Johnson Announces Results from the Phase 2 Open-Label UNITY Study of Nipocalimab for the Treatment of Alloimmunized Pregnant Individuals

Johnson & Johnson Announces Darzalex Faspro® (Daratumumab and Hyaluronidase-Fihj)-Based Quadruplet Regimen Approved in the U.S. for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible

Consensus EPS estimates fall by 10%

Johnson & Johnson Seeks U.S. FDA Approval of Spravato (Esketamine) as the First and Only Monotherapy for Adults with Treatment-Resistant Depression

Johnson & Johnson Announces Quarterly Cash Dividend for Third Quarter of 2024, Payable on September 10, 2024

Johnson & Johnson Q2: Robust New Product Pipeline

Johnson & Johnson Announces Quarterly Cash Dividend for Third Quarter of 2024, Payable on September 10, 2024

Johnson & Johnson Q2 Earnings Preview: Scrutinizing Its Earnings Quality

Johnson & Johnson: A Lot Of Moving Parts, But Perhaps Finally Lurching In The Right Direction

Johnson & Johnson Announces Positive Results from Prespecified Second Interim Analysis of the Phase 3 CARTITUDE-4 Study Evaluating CARVYKTI

Johnson & Johnson Announces Positive Results from the Nipocalimab Phase 3 Vivacity-MG3 Study

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.

Beasley Allen and Levin Papantonio Announces Class Action Lawsuit Against Johnson & Johnson

Johnson & Johnson Announces TALVEY® (Talquetamab-Tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma

There's Reason For Concern Over Johnson & Johnson's (NYSE:JNJ) Price

New major risk - Revenue and earnings growth

Johnson & Johnson to Report Q3, 2024 Results on Oct 15, 2024

Johnson & Johnson Announces Results from a Subgroup Analysis of the Phase 3 CARTITUDE-4 Study

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견